The FDA approved an RSV (respiratory syncytial virus) vaccine for people age 50 and up. The vaccine, manufactured by GSK, was already approved for use in individuals age 60 and older. For the first time, people younger than 60 can receive a vaccine to prevent severe disease from the RSV. While the virus is particularly dangerous to older adults and young children, middle-aged people who have certain chronic diseases are also vulnerable. Adults with conditions such as asthma, COPD and diabetes face an elevated risk of suffering life-threatening health outcomes if they get infected with RSV. These individuals have a higher chance of developing pneumonia, being hospitalized and dying.
The next step in the vaccine’s review process will be for the CDC to review the application, which is expected to happen in June and October. If the agency’s committee of experts gives its approval, the vaccine will be eligible for insurance coverage.
Full Story: HealthDay
